XIAP and retinal degeneration: In addition, rd10 mice first treated with AAV5-XIAP at P4, then subsequently treated with AAV5-PDEβ after 2 weeks in the light, respond with a dramatic slowing of further retinal degeneration that is not achieved by gene-replacement therapy in animals of the same age who have not received prior XIAP treatment.